Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Nephrology
Published in: Clinical and Experimental Nephrology 1/2015

01-02-2015 | Guideline

Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: general therapy

Authors: Yoshitsugu Kaku, Yasufumi Ohtsuka, Yasuhiro Komatsu, Toshiyuki Ohta, Takuhito Nagai, Hiroshi Kaito, Shuji Kondo, Yohei Ikezumi, Seiji Tanaka, Shinsuke Matsumoto, Mayumi Sako, Kazushi Tsuruga, Koichi Nakanishi, Koichi Kamei, Hiroshi Saito, Shuichiro Fujinaga, Yuko Hamasaki, Hiroko Chikamoto, Kenji Ishikura, Kazumoto Iijima

Published in: Clinical and Experimental Nephrology | Issue 1/2015

Login to get access

Excerpt

Pediatric idiopathic nephrotic syndrome is a very important disease in the field of pediatric nephrology. The Japanese Society for Pediatric Nephrology published the “Clinical Practice Guideline for Medical Treatment of Pediatric Idiopathic Nephrotic Syndrome (version 1.0) (in Japanese)” in 2005. The guideline, aiming to support appropriate decision and treatment for pediatric idiopathic nephrotic syndrome, illustrated standard regimens of medical treatment of pediatric idiopathic nephrotic syndrome at that time and has been credited with standardization and optimization of the treatment. In 2011, 6 years after the publication, the need to revise the guideline became recognized against the background of changes in care setting including introduction of rituximab. Additionally, development of guideline covering general therapies was required. …
Literature
1.
Ishikura K, Matsumoto S, Sako M, Tsuruga K, Nakanishi K, Kamei K, Saito H, Fujinaga S, Hamasaki Y, Chikamoto H, Ohtsuka Y, Komatsu Y, Ohta T, Nagai T, Kaito H, Kondo S, Ikezumi Y, Tanaka S, Kaku Y, Iijima K. Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy, clinical and experimental nephrology. doi:10.​1007/​s10157-014-1030-x.
2.
Gipson DS, Massengill SF, Yao L, Nagaraj S, Smoyer WE, Mahan JD, Wigfall D, Miles P, Powell L, Lin JJ, Trachtman H, Greenbaum LA. Management of childhood onset nephrotic syndrome. Pediatrics. 2009;124(2):747–57.CrossRefPubMed
3.
Indian Pediatric Nephrology Group, Indian Academy of Pediatrics, Bagga A, Ali U, Banerjee S, Kanitkar M, Phadke KD, Senguttuvan P, Sethi S, Shah M. Management of steroid sensitive nephrotic syndrome: revised guidelines. Indian Pediatr. 2008;45(3):203–14.
4.
Vasudevan A, Mantan M, Bagga A. Management of edema in nephrotic syndrome. Indian Pediatr. 2004;41(8):787–95.PubMed
5.
6.
Doucet A, Favre G, Deschênes G. Molecular mechanism of edema formation in nephrotic syndrome: therapeutic implications. Pediatr Nephrol. 2007;22(12):1983–90.CrossRefPubMedCentralPubMed
7.
Siddall EC, Radhakrishnan J. The pathophysiology of edema formation in the nephrotic syndrome. Kidney Int. 2012;82(6):635–42.CrossRefPubMed
8.
Avner ED, Harmon WE, Niaudet P, Yoshikawa N, editors. Pediatric nephrology. 6th ed. Baltimore: Lippincott Williams and Wilkins; 2009.
9.
Vande Walle JG, Donckerwolcke RA, van Isselt JW, Derkx FH, Joles JA, Koomans HA. Volume regulation in children with early relapse of minimal-change nephrosis with or without hypovolaemic symptoms. Lancet. 1995;15:148–52.
10.
Wang SJ, Tsau YK, Lu FL, Chen CH. Hypovolemia and hypovolemic shock in children with nephrotic syndrome. Acta Paediatr Taiwan. 2000;41:179–83.PubMed
11.
Vande Walle JG, Donckerwolcke RA, Koomans HA. Pathophysiology of edema formation in children with nephrotic syndrome not due to minimal change disease. J Am Soc Nephrol. 1999;10:323–31.PubMed
12.
Van de Walle JG, Donckerwolcke RA, Greidanus TB, Joles JA, Koomans HA. Renal sodium handling in children with nephrotic relapse: relation to hypovolaemic symptoms. Nephrol Dial Transplant. 1996;11:2202–8.CrossRefPubMed
13.
14.
Haws RM, Baum M. Efficacy of albumin and diuretic therapy in children with nephrotic syndrome. Pediatrics. 1993;91:1142–6.PubMed
15.
Agarwal N, Phadke KD, Garg I, Alexander P. Acute renal failure in children with idiopathic nephrotic syndrome. Pediatr Nephrol. 2003;18:1289–92.CrossRefPubMed
16.
Loghman-Adham M, Siegler RL, Pysher TJ. Acute renal failure in idiopathic nephrotic syndrome. Clin Nephrol. 1997;47:76–80.PubMed
17.
Sakarcan A, Timmons C, Seikaly MG. Reversible idiopathic acute renal failure in children with primary nephrotic syndrome. J Pediatr. 1994;125(5 Pt 1):723–7.CrossRefPubMed
18.
Gurgoze MK, Gunduz Z, Poyrazoglu MH, Dursun I, Uzum K, Dusunsel R. Role of sodium during formation of edema in children with nephrotic syndrome. Pediatr Int. 2011;53:50–6.CrossRefPubMed
19.
Dönmez O, Mir S, Ozyürek R, Cura A, Kabasakal C. Inferior vena cava indices determine volume load in minimal lesion nephrotic syndrome. Pediatr Nephrol. 2001;16:251–5.CrossRefPubMed
20.
Tabel Y, Mungan I, Karakurt C, Kocak G, Gungor S. Is edema in minimal change disease of childhood really hypovolemic? Int Urol Nephrol. 2008;40:757–61.CrossRefPubMed
21.
Donckerwolcke RA, France A, Raes A, Vande Walle J. Distal nephron sodium–potassium exchange in children with nephrotic syndrome. Clin Nephrol. 2003;59:259–66.CrossRefPubMed
22.
Kapur G, Valentini RP, Imam AA, Jain A, Mattoo TK. Serum osmolal gap in patients with idiopathic nephrotic syndrome and severe edema. Pediatrics. 2007;119(6):e1404–7.CrossRefPubMed
23.
Bozzetto S, Piccoli A, Montini G. Bioelectrical impedance vector analysis to evaluate relative hydration status. Pediatr Nephrol. 2010;25:329–34.CrossRefPubMed
24.
van der Vorst MM, Kist JE, van der Heijden AJ, Burggraaf J. Diuretics in pediatrics: current knowledge and future prospects. Paediatr Drugs. 2006;8(4):245–64.CrossRefPubMed
25.
Eades SK, Christensen ML. The clinical pharmacology of loop diuretics in the pediatric patient. Pediatr Nephrol. 1998;12(7):603–16.CrossRefPubMed
26.
Prandota J. Pharmacokinetics of furosemide urinary elimination by nephrotic children. Pediatr Res. 1983;17(2):141–7.CrossRefPubMed
27.
28.
Garin EH. A comparison of combinations of diuretics in nephrotic edema. Am J Dis Child. 1987;141:769–71.PubMed
29.
Kapur G, Valentini RP, Imam AA, Mattoo TK. Treatment of severe edema in children with nephrotic syndrome with diuretics alone—a prospective study. Clin J Am Soc Nephrol. 2009;4:907–13.CrossRefPubMedCentralPubMed
30.
Dharmaraj R, Hari P, Bagga A. Randomized cross-over trial comparing albumin and frusemide infusions in nephrotic syndrome. Pediatr Nephrol. 2009;24:775–82.CrossRefPubMed
31.
32.
Kanzaki M, Wada J, Kikumoto Y, Akagi S, Nakao K, Sugiyama H, Makino H. The therapeutic potential of synthetic human atrial natriuretic peptide in nephrotic syndrome: a randomized controlled trial. Int J Nephrol Renovasc Dis. 2012;5:91–6.PubMedCentralPubMed
33.
Bircan Z, Kervancioğlu M, Katar S, Vitrinel A. Does albumin and furosemide therapy affect plasma volume in nephrotic children? Pediatr Nephrol. 2001;16:497–9.CrossRefPubMed
34.
Fauchald P, Noddeland H, Norseth J. An evaluation of ultrafiltration as treatment of diuretic-resistant oedema in nephrotic syndrome. Acta Med Scand. 1985;217:127–31.CrossRefPubMed
35.
Kaysen GA, Gambertoglio J, Jimenez I, Jones H, Hutchison FN. Effect of dietary protein intake on albumin homeostasis in nephrotic patients. Kidney Int. 1986;29:572–7.CrossRefPubMed
36.
Rosenberg ME, Swanson JE, Thomas BL, Hostetter TH. Glomerular and hormonal responses to dietary protein intake in human renal disease. Am J Physiol 1987;253 F1083–F1090.
37.
Poortmans JR, Vanderstraeten J. Kidney function during exercise in healthy and diseased humans. An update. Sports Med. 1994;18:419–37.CrossRefPubMed
38.
Nagasaka Y, Yogi S, Taguchi H, Yoshida Y, Fujiwara Y. Participation to swimming lessons and relapse of nephrotic syndrome [in Japanese]. J Jpn Pediatr Soc. 1986;90:2737–41.
39.
Nagasaka Y. The effect of swimming on renal function in children with renal disease [in Japanese]. Jpn J Nephrol. 1986;28:1465–70.
40.
Miura H, Fukui H, Hayano K, Otsuka Y, Hattori S. A case of minimal change nephrotic syndrome associated with acute renal failure after excessive exercise. Nihon Jinzo Gakkai Shi. 1993;35:387–91.PubMed
41.
Kayali F, Najjar R, Aswad F, Matta F, Stein PD. Venous thromboembolism in patients hospitalized with nephrotic syndrome. Am J Med. 2008;121(3):226–30.CrossRefPubMed
42.
Hoyer PF, Gonda S, Barthels M, Krohn HP, Brodehl J. Thromboembolic complications in children with nephrotic syndrome. Risk and incidence. Acta Paediatr Scand. 1986;75:804–10.CrossRefPubMed
43.
Kerlin BA, Blatt NB, Fuh B, Zhao S, Lehman A, Blanchong C, Mahan JD, Smoyer WE. Epidemiology and risk factors for thromboembolic complications of childhood nephrotic syndrome: a Midwest Pediatric Nephrology Consortium (MWPNC) Study. J Pediatr. 2009;155:105–10.CrossRefPubMedCentralPubMed
44.
Lilova MI, Velkovski IG, Topalov IB. Thromboembolic complications in children with nephrotic syndrome in Bulgaria (1974–1996). Pediatr Nephrol. 2000;15:74–8.CrossRefPubMed
45.
Hegarty J, Mughal MZ, Adams J, Webb NJ. Reduced bone mineral density in adults treated with high-dose corticosteroids for childhood nephrotic syndrome. Kidney Int. 2005;68:2304–9.CrossRefPubMed
46.
Foster BJ, Shults J, Zemel BS, Leonard MB. Risk factors for glucocorticoid-induced obesity in children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2006;21:973–80.CrossRefPubMed
47.
Merritt RJ, Hack SL, Kalsch M, Olson D. Corticosteroid therapy-induced obesity in children. Clin Pediatr (Phila). 1986;25:149–52.CrossRef
48.
Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, Allen K, Lopes M, Savoye M, Morrison J, Sherwin RS, Caprio S. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004;350:2362–74.CrossRefPubMed
49.
Savoye M, Shaw M, Dziura J, Tamborlane WV, Rose P, Guandalini C, Goldberg-Gell R, Burgert TS, Cali AM, Weiss R, Caprio S. Effects of a weight management program on body composition and metabolic parameters in overweight children: a randomized controlled trial. JAMA. 2007;297:2697–704.CrossRefPubMed
50.
Goto M, Ninomiya M, Uemura O, Matsuyama K, Ito Y, Hataya H, Ito S, Yamakawa S, Ishikawa T, Honda M. A questionnaire survey on exercise limitation in children with kidney disease [in Japanese]. Jpn J Pediatr Nephrol. 2012;25(6):17.
51.
van Staa TP, Cooper C, Leufkens HG, Bishop N. Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res. 2003;18(5):913–8.CrossRefPubMed
52.
Leonard MB, Feldman HI, Shults J, Zemel BS, Foster BJ, Stallings VA. Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome. N Engl J Med. 2004;351:868–75.CrossRefPubMed
53.
Freundlich M, Jofe M, Goodman WG, Salusky IB. Bone histology in steroid-treated children with non-azotemic nephrotic syndrome. Pediatr Nephrol. 2004;19:400–7.CrossRefPubMed
54.
Reyes ML, Hernández MI, King A, Vinet AM, Vogel A, Lagomarsino E, Mericq MV, Méndez C, Gederlini A, Talesnik E. Corticosteroid-induced osteoporosis in children: outcome after two-year follow-up, risk factors, densitometric predictive cut-off values for vertebral fractures. Clin Exp Rheumatol. 2007;25:329–35.PubMed
55.
Rudge S, Hailwood S, Horne A, Lucas J, Wu F, Cundy T. Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology (Oxford). 2005;44(6):813–8.CrossRef
56.
Bak M, Serdaroglu E, Guclu R. Prophylactic calcium and vitamin D treatments in steroid-treated children with nephrotic syndrome. Pediatr Nephrol. 2006;21:350–4.CrossRefPubMed
57.
Kaiser BA, Polinsky MS, Palmer JA, Dunn S, Mochon M, Flynn JT, Baluarte HJ. Growth after conversion to alternate-day corticosteroids in children with renal transplants: a single-center study. Pediatr Nephrol. 1994;8:320–5.CrossRefPubMed
58.
Broyer M, Guest G, Gagnadoux MF. Growth rate in children receiving alternate-day corticosteroid treatment after kidney transplantation. J Pediatr. 1992;120:721–5.CrossRefPubMed
59.
Guest G, Broyer M. Growth after renal transplantation: correlation with immunosuppressive therapy. Pediatr Nephrol. 1991;5:143–6.CrossRefPubMed
60.
Hokken-Koelega AC, Van Zaal MA, de Ridder MA, Wolff ED, De Jong MC, Donckerwolcke RA, De Muinck Keizer-Schrama SM, Drop SL. Growth after renal transplantation in prepubertal children: impact of various treatment modalities. Pediatr Res. 1994;35:367–71.CrossRefPubMed
61.
Jabs K, Sullivan EK, Avner ED, Harmon WE. Alternate-day steroid dosing improves growth without adversely affecting graft survival or long-term graft function. A report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation. 1996;61:31.CrossRefPubMed
62.
Yamashita F, Funatsu T, Nagayama K, Arihiro H, Anan S. Evaluation of alternate-day steroid therapy for nephrotic syndrome in childhood by cross-over study. Kurume Med J. 1971;18:153–60.CrossRefPubMed
63.
Kimura Y, Fieldston E, Devries-Vandervlugt B, Li S, Imundo L. High dose, alternate day corticosteroids for systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2000;27:2018–24.PubMed
64.
Simmonds J, Trompeter R, Tullus K. Long-term steroid treatment and growth: a study in steroid-dependent nephrotic syndrome. Arch Dis Child. 2010;95:146–9.CrossRefPubMed
65.
Rivkees SA, Danon M, Herrin J. Prednisone dose limitation of growth hormone treatment of steroid-induced growth failure. J Pediatr. 1994;125:322–5.
66.
Bachmann HJ, Schildberg P, Olbing H, Krämer D, Waubke T. Cortisone cataract in children with nephrotic syndrome. Eur J Pediatr. 1977;124:277–83.CrossRefPubMed
67.
Brocklebank JT, Harcourt RB, Meadow SR. Corticosteroid-induced cataracts in idiopathic nephrotic syndrome. Arch Dis Child. 1982;57:30–4.PubMedCentralPubMed
68.
Forman AR, Loreto JA, Tina LU. Reversibility of corticosteroid-associated cataracts in children with the nephrotic syndrome. Am J Ophthalmol. 1977;84:75–8.CrossRefPubMed
69.
Limaye SR, Pillai S, Tina LU. Relationship of steroid dose to degree of posterior subcapsular cataracts in nephrotic syndrome. Ann Ophthalmol. 1988;20:225–7.PubMed
70.
Kobayashi Y, Akaishi K, Nishio T, Kobayashi Y, Kimura Y. Posterior subcapsular cataract in nephrotic children receiving steroid therapy. Am J Dis Child. 1974;128:671–3.PubMed
71.
Hayasaka Y, Hayasaka S, Matsukura H. Ocular findings in Japanese children with nephrotic syndrome receiving prolonged corticosteroid therapy. Ophthalmologica. 2006;220:181–5.CrossRefPubMed
72.
Kaye LD, Kalenak JW, Price RL, Cunningham R. Ocular implications of long-term prednisone therapy in children. J Pediatr Ophthalmol Strabismus. 1993;30:142–4.
73.
Ng JS, Wong W, Law RW, Hui J, Wong EN, Lam DS. Ocular complications of paediatric patients with nephrotic syndrome. Clin Exp Ophthalmol. 2001;29:239–43.CrossRef
74.
Chen CH, Chen CM. Lee PP. The effect of betamethasone on intraocular pressure in nephrotic children. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1994;35:197–201.PubMed
75.
Alwadhi RK, Mathew JL, Rath B. Clinical profile of children with nephrotic syndrome not on glucorticoid therapy, but presenting with infection. J Paediatr Child Health. 2004;40:28–32.CrossRefPubMed
76.
Dowell SF, Bresee JS. Severe varicella associated with steroid use. Pediatrics. 1993;92:223–8.PubMed
77.
Uncu N, Bülbül M, Yildiz N, Noyan A, Koşan C, Kavukçu S, Calişkan S, Gündüz Z, Beşbaş N. Gür Güven A. Primary peritonitis in children with nephrotic syndrome: results of a 5-year multicenter study. Eur J Pediatr. 2010;169:73–6.CrossRefPubMed
78.
Tain YL, Lin G, Cher TW. Microbiological spectrum of septicemia and peritonitis in nephrotic children. Pediatr Nephrol. 1999;13:835–7.CrossRefPubMed
79.
Hsu K, Pelton S, Karumuri S, Heisey-Grove D, Klein J. Massachusetts Department of Public Health Epidemiologists. Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine. Pediatr Infect Dis J. 2005;24:17–23.CrossRefPubMed
80.
Ulinski T, Leroy S, Dubrel M, Danon S, Bensman A. High serological response to pneumococcal vaccine in nephrotic children at disease onset on high-dose prednisone. Pediatr Nephrol. 2008;23:1107–13.CrossRefPubMed
81.
Aoun B, Wannous H, Azéma C, Ulinski T. Polysaccharide pneumococcal vaccination of nephrotic children at disease onset-long-term data. Pediatr Nephrol. 2010;25:1773–4.CrossRefPubMed
82.
Liakou CD, Askiti V, Mitsioni A, Stefanidis CJ, Theodoridou MC, Spoulou VI. Safety, immunogenicity and kinetics of immune response to 7-valent pneumococcal conjugate vaccine in children with idiopathic nephrotic syndrome. Vaccine. 2011;16(29):6834–7.CrossRef
83.
Poyrazoğlu HM, Düşünsel R, Gündüz Z, Patiroğlu T, Köklü S. Antibody response to influenza A vaccination in children with nephrotic syndrome. Pediatr Nephrol. 2004;19:57–60.CrossRefPubMed
84.
Laube GF, Berger C, Goetschel P, Leumann E, Neuhaus TJ. Immunization in children with chronic renal failure. Pediatr Nephrol. 2002;17:638–42.CrossRefPubMed
85.
Furth SL, Arbus GS, Hogg R, Tarver J, Chan C, Fivush BA, Southwest Pediatric Nephrology Study Group. Varicella vaccination in children with nephrotic syndrome: a report of the Southwest Pediatric Nephrology Study Group. J Pediatr. 2003;142:145–8.CrossRefPubMed
86.
Goldstein SL, Somers MJ, Lande MB, Brewer ED, Jabs KL. Acyclovir prophylaxis of varicella in children with renal disease receiving steroids. Pediatr Nephrol. 2000;14:305–8.CrossRefPubMed
87.
Trompeter RS, Lloyd BW, Hicks J, White RH, Cameron JS. Long-term outcome for children with minimal-change nephrotic syndrome. Lancet. 1985;1:368–70.CrossRefPubMed
88.
Wynn SR, Stickler GB, Burke EC. Long-term prognosis for children with nephrotic syndrome. Clin Pediatr (Phila). 1988;27:63–8.CrossRef
89.
Fakhouri F, Bocquet N, Taupin P, Presne C, Gagnadoux MF, Landais P, Lesavre P, Chauveau D, Knebelmann B, Broyer M, Grünfeld JP, Niaudet P. Steroid-sensitive nephrotic syndrome: from childhood to adulthood. Am J Kidney Dis. 2003;41:550–7.CrossRefPubMed
90.
Rüth EM, Kemper MJ, Leumann EP, Laube GF, Neuhaus TJ. Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome. J Pediatr. 2005;147:202–7.CrossRefPubMed
91.
Ishimori S, Kaito H, Ohtsubo H, Hashimoto F, Ninchoji T, Hashimura Y, Morisada N, Iijima K. Current status and complications of adult patients with childhood-onset steroid-sensitive nephrotic syndrome [in Japanese]. J Jpn Pediatr Soc. 2013;117:90–6.
Metadata
Title
Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: general therapy
Authors
Yoshitsugu Kaku
Yasufumi Ohtsuka
Yasuhiro Komatsu
Toshiyuki Ohta
Takuhito Nagai
Hiroshi Kaito
Shuji Kondo
Yohei Ikezumi
Seiji Tanaka
Shinsuke Matsumoto
Mayumi Sako
Kazushi Tsuruga
Koichi Nakanishi
Koichi Kamei
Hiroshi Saito
Shuichiro Fujinaga
Yuko Hamasaki
Hiroko Chikamoto
Kenji Ishikura
Kazumoto Iijima
Publication date
01-02-2015
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 1/2015
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-014-1031-9

Other articles of this Issue 1/2015

Clinical and Experimental Nephrology 1/2015 Go to the issue

Images in Nephrology

Copper beaten skull in X-linked hypophosphataemic rickets

Original Article

Alpha-lipoic acid attenuates lipopolysaccharide-induced kidney injury

Letter to the Editor

Seasonal variation in first episode of childhood idiopathic steroid-sensitive nephrotic syndrome and adult minimal change nephrotic syndrome

Original Article

Relationship of late arteriovenous fistula stenosis with soluble E-selectin and soluble EPCR in chronic hemodialysis patients with arteriovenous fistula

Letter to the Editor

Prevalence of colorectal carcinoma in CKD patients in pre-dialysis and during the dialysis introduction period

Original Article

Tumor necrosis factor-α synergistically enhances polyinosinic-polycytidylic acid-induced toll-like receptor 3 signaling in cultured normal human mesangial cells: possible involvement in the pathogenesis of lupus nephritis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits